Erratum to: Comparative Pharmacoeconomic Effectiveness of Interleukin-17 Inhibitors for the Treatment of Ankylosing Spondylitis

T. V. Dubinina,I. Z. Gaidukova,N. A. Sableva,K. V. Sapozhnikov,V. D. Sokolova,D. G. Tolkacheva

DOI: https://doi.org/10.1134/s1607672923050058

2024-01-25

Doklady Biochemistry and Biophysics

Abstract:An Erratum to this paper has been published: https://doi.org/10.1134/S1607672923050058

biochemistry & molecular biology,biophysics

What problem does this paper attempt to address?

Erratum to: Different Clinical Relevance of Anti-Citrullinated Protein Antibodies in RA Patients

A. S. Avdeeva,M. V. Cherkasova,E. L. Nasonov

DOI: https://doi.org/10.1134/s1607672923050034

2024-01-25

Doklady Biochemistry and Biophysics

Abstract:An Erratum to this paper has been published: https://doi.org/10.1134/S1607672923050034

biochemistry & molecular biology,biophysics
Erratum to: Are the Goals of Therapy Achievable in Patients with Rheumatoid Arthritis Receiving Upadacitinib in Real Clinical Practice?

V. N. Amirdzhanova,A. E. Karateev,E. Yu. Pogozheva,E. S. Filatova,R. R. Samigullina,V. I. Mazurov,O. N. Anoshenkova,N. A. Lapkina,A. A. Baranov,T. Yu. Grineva,A. M. Lila,E. L. Nasonov

DOI: https://doi.org/10.1134/s1607672923050010

2024-01-25

Doklady Biochemistry and Biophysics

Abstract:An Erratum to this paper has been published: https://doi.org/10.1134/S1607672923050010

biochemistry & molecular biology,biophysics
Erratum to: Anti-topoisomerase 1 Antibody Level Changes after B Cell Depletion Therapy in Systemic Sclerosis

L. P. Ananyeva,L. A. Garzanova,O. A. Koneva,M. N. Starovoytova,O. V. Desinova,O. B. Ovsyannikova,R. U. Shayakhmetova,M. V. Cherkasova,A. P. Aleksankin,E. L. Nasonov

DOI: https://doi.org/10.1134/s1607672923050022

2024-01-25

Doklady Biochemistry and Biophysics

Abstract:An Erratum to this paper has been published: https://doi.org/10.1134/S1607672923050022

biochemistry & molecular biology,biophysics
Corrigendum to Tildrakizumab Inadequate Responders Switching to an Alternative IL-23 Inhibitor: A Case Series

DOI: https://doi.org/10.1177/24755303231195883

Abstract:[This corrects the article DOI: 10.1177/24755303211037308.].
Corrigendum: Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum

Francisca Sivera,Victoria Núñez-Monje,Cristina Campos-Fernández,Isabel Balaguer-Trull,Montserrat Robustillo-Villarino,Marta Aguilar-Zamora,Marta Garijo-Bufort,Juan Miguel López-Gómez,Carolina Peña-González,Isabel de la Morena,Diego Bedoya-Sanchís,Liliya Yankova-Komsalova,Arantxa Conesa-Mateos,Anna Martínez-Cristóbal,Francisco Javier Navarro-Blasco,José Miguel Senabre-Gallego,Juan José Alegre-Sancho

DOI: https://doi.org/10.3389/fmed.2024.1462054

2024-09-10

Abstract:[This corrects the article DOI: 10.3389/fmed.2023.1156557.].
Corrigendum: Efficacy and safety of Janus kinase inhibitors in non-infectious inflammatory ocular diseases: a prospective cohort study from the international AIDA network registries

Antonio Vitale,Judith Palacios-Olid,Valeria Caggiano,Gaafar Ragab,José Hernández-Rodríguez,Laura Pelegrín,Germán Mejía-Salgado,Laura Zarate-Pinzón,Stefano Gentileschi,Jurgen Sota,Alex Fonollosa,Ester Carreño,Carla Gaggiano,Rana Hussein Amin,Alberto Balistreri,Javier Narváez,Gian Marco Tosi,Bruno Frediani,Luca Cantarini,Alejandra de-la-Torre,Claudia Fabiani

DOI: https://doi.org/10.3389/fmed.2024.1489092

2024-09-13

Abstract:[This corrects the article DOI: 10.3389/fmed.2024.1439338.].
Erratum: Reichenbach DK, Schwarze V, Matta BM, et al. The IL-33/ST2 axis augments effector T-cell responses during acute GVHD. Blood. 2015;125(20):3183-3192

DOI: https://doi.org/10.1182/blood-2016-07-728048

IF: 20.3

2016-09-01

Blood

Abstract:[This corrects the article DOI: 10.1182/blood-2014-10-606830.].
Erratum to: Antibodies to Domain I β2-Glycoprotein 1 in Patients with Antiphospholipid Syndrome and Systemic Lupus Erythematosus

T. M. Reshetnyak,F. A. Cheldieva,M. V. Cherkasova,S. I. Glukhova,A. M. Lila,E. L. Nasonov

DOI: https://doi.org/10.1134/s160767292305006x

2024-01-25

Doklady Biochemistry and Biophysics

Abstract:An Erratum to this paper has been published: https://doi.org/10.1134/S160767292305006X

biochemistry & molecular biology,biophysics
Erratum: Role of PCSK9 inhibition during the inflammatory stage of SARS-COV-2: an updated review: Erratum

DOI: https://doi.org/10.1097/MS9.0000000000002497

2024-09-04

Abstract:[This corrects the article DOI: 10.1097/MS9.0000000000001601.].
Erratum: Addendum of Conflict of Interest

Journal Of Rheumatic Diseases Editorial Office

DOI: https://doi.org/10.4078/jrd.2023e1

2023-01-01

Abstract:[This corrects the article on p. 0 in vol. 0.].
Corrigendum: Poor prognostic factors of pharmacokinetic origin predict outcomes in inflammatory bowel disease patients treated with anti-tumor necrosis factor-α

Elizabeth A. Spencer,Marla C. Dubinsky,Michael A. Kamm,Maria Chaparro,Paolo Gionchetti,Fernando Rizzello,Javier P. Gisbert,Emily K. Wright,Julien D. Schulberg,Amy L. Hamilton,Dermot P. B. McGovern,Thierry Dervieux

DOI: https://doi.org/10.3389/fimmu.2024.1383704

IF: 7.3

2024-02-28

Frontiers in Immunology

Abstract:This article is a correction to: A Novel Model Based on Serum Biomarkers to Predict Primary Non-Response to Infliximab in Crohn's Disease

immunology
Erratum: She-Chuang-Si-Wu-Tang Alleviates Inflammation and Itching Symptoms in a Psoriasis Mouse Model by Regulating the Th17/IL-17 Axis via the STAT3/MAPK Pathways [Corrigendum]

DOI: https://doi.org/10.2147/JIR.S499600

2024-10-11

Abstract:[This corrects the article DOI: 10.2147/JIR.S472417.].
Corrigendum to Dosage Adjustments in Patients With Psoriasis on Etanercept: A Retrospective Chart Review

DOI: https://doi.org/10.1177/24755303231195871

Abstract:[This corrects the article DOI: 10.1177/2475530320910466.].
Erratum: Zeiser R, Blazar BR. Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation? Blood. 2016;127(25):3117-3126

DOI: https://doi.org/10.1182/blood-2016-07-730580

IF: 20.3

2016-09-08

Blood

Abstract:[This corrects the article DOI: 10.1182/blood-2016-02-699082.].
Corrigendum: Treatment sequence after initiating biologic therapy for patients with rheumatoid arthritis in Korea: a nationwide retrospective cohort study

Min Jung Kim,Jun Won Park,Sun-Kyung Lee,Yumi Jang,Soyoung Kim,Matthias Stoelzel,Jonathan Lumen Chua,Kichul Shin

DOI: https://doi.org/10.4078/jrd.22.0024C

2024-10-01

Abstract:[This corrects the article on p. 26 in vol. 30, PMID: 37476522.].
Correction to Lancet Rheumatol 2020; 2: e557-64

DOI: https://doi.org/10.1016/S2665-9913(21)00137-5

Abstract:[This corrects the article DOI: 10.1016/S2665-9913(20)30227-7.].
Erratum: Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab

Frontiers Production Office

DOI: https://doi.org/10.3389/fphar.2022.1092147

IF: 5.6

2022-11-22

Frontiers in Pharmacology

Abstract:[This corrects the article DOI: 10.3389/fphar.2022.973448.].

pharmacology & pharmacy
Corrigendum to Antibody Response to BNT162b2 Vaccine in Immune Modifiers-Treated Psoriatic Patients

DOI: https://doi.org/10.1177/24755303231195874

Abstract:[This corrects the article DOI: 10.1177/24755303211056059.].
Erratum: "A double-blind randomised controlled trial of protein supplementation to enhance exercise capacity in COPD during pulmonary rehabilitation: a pilot study". Abdulelah M. Aldhahir, Yousef S. Aldabayan, Jaber S. Alqahtani, Heidi A. Ridsdale, Colette Smith, John R. Hurst and Swapna Mandal. ERJ Open Res 2021; 7: 00077-2021

DOI: https://doi.org/10.1183/23120541.50077-2021

2022-10-24

Abstract:[This corrects the article DOI: 10.1183/23120541.00077-2021.].
Correspondence on ‘Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort’ by Micheroli et al

Jin-Xian Huang,Pui-Ying Leong,James Cheng-Chung Wei

DOI: https://doi.org/10.1136/annrheumdis-2020-218779

IF: 27.973

2020-09-15

Annals of the Rheumatic Diseases

Abstract:We read with great interest the article by Micheroli et al1 for comparison of effectiveness between secukinumab (SEC) and tumour necrosis factor inhibitor (TNFi) in axial spondylitis (axSpA), with evidence conform to the current recommendation in a Swiss real-world setting. According to current guidelines,2 3 4interleukin-17 inhibitor (IL-17i) or alternative TNFi are both recommended as the switch option of biological disease-modifying antirheumatic drug in patients with previous TNFi failure. Although head-to-head comparison clinical trials between IL-17 inhibition and TNF blockade have been conducted in psoriatic arthritis recently5 6 and is ongoing in axSpA, we appreciated Micheroli et al1 for their new information in this real-world indirect comparison study. However, some issues can be further discussed. First, regarding the study design, it was not mentioned whether treatment adjustment was due to drug inefficacy or intolerability and...

rheumatology

Erratum to: Comparative Pharmacoeconomic Effectiveness of Interleukin-17 Inhibitors for the Treatment of Ankylosing Spondylitis

Erratum to: Different Clinical Relevance of Anti-Citrullinated Protein Antibodies in RA Patients

Erratum to: Are the Goals of Therapy Achievable in Patients with Rheumatoid Arthritis Receiving Upadacitinib in Real Clinical Practice?

Erratum to: Anti-topoisomerase 1 Antibody Level Changes after B Cell Depletion Therapy in Systemic Sclerosis

Corrigendum to Tildrakizumab Inadequate Responders Switching to an Alternative IL-23 Inhibitor: A Case Series

Corrigendum: Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum

Corrigendum: Efficacy and safety of Janus kinase inhibitors in non-infectious inflammatory ocular diseases: a prospective cohort study from the international AIDA network registries

Erratum: Reichenbach DK, Schwarze V, Matta BM, et al. The IL-33/ST2 axis augments effector T-cell responses during acute GVHD. Blood. 2015;125(20):3183-3192

Erratum to: Antibodies to Domain I β2-Glycoprotein 1 in Patients with Antiphospholipid Syndrome and Systemic Lupus Erythematosus

Erratum: Role of PCSK9 inhibition during the inflammatory stage of SARS-COV-2: an updated review: Erratum

Erratum: Addendum of Conflict of Interest

Corrigendum: Poor prognostic factors of pharmacokinetic origin predict outcomes in inflammatory bowel disease patients treated with anti-tumor necrosis factor-α

Erratum: She-Chuang-Si-Wu-Tang Alleviates Inflammation and Itching Symptoms in a Psoriasis Mouse Model by Regulating the Th17/IL-17 Axis via the STAT3/MAPK Pathways [Corrigendum]

Corrigendum to Dosage Adjustments in Patients With Psoriasis on Etanercept: A Retrospective Chart Review

Erratum: Zeiser R, Blazar BR. Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation? Blood. 2016;127(25):3117-3126

Corrigendum: Treatment sequence after initiating biologic therapy for patients with rheumatoid arthritis in Korea: a nationwide retrospective cohort study

Correction to Lancet Rheumatol 2020; 2: e557-64

Erratum: Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab

Corrigendum to Antibody Response to BNT162b2 Vaccine in Immune Modifiers-Treated Psoriatic Patients

Correspondence on ‘Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort’ by Micheroli et al